Daniel Rodríguez Muñoz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Rodríguez Muñoz has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
José Luis Zamorano Gómez
Cardiology Department, University Hospital Ramon y Cajal , Madrid
10 shared publicationsJavier Moreno
Cardiology Department, University Hospital Ramon y Cajal, Madrid, Spain
8 shared publications- Javier Ramos Jiménez
Cardiology Department, Hospital Universitario 12 de Octubre , Glorieta de Malaga 11, 28041 Madrid
8 shared publications - Álvaro Marco del Castillo
12 de Octubre University Hospital, Madrid, Spain
8 shared publications José Luis Moya Mur
Cardiology Department, University Hospital Ramon y Cajal, Madrid, Spain
7 shared publications- Rafael Salguero-Bodes
Department of Cardiology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
7 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1880750
Extent of posterior wall lesion following pulmonary vein isolation with pentaspline pulsed field and cryoballoon ablation: the potential role of deployment technique
Background: Pulmonary vein isolation (PVI) using cryoballoon (CB) or pulsed field ablation (PFA) with a pentaspline catheter achieves similar efficacy in atrial fibrillation (AF), but lesion extension on the left atrial posterior wall (LAPW) may differ. Pentaspline-PFA (P-PFA) has been reported to create broader LAPW lesions, potentially leaving narrow viable corridors that have been hypothesized to be proarrhythmic. Objective: To descriptively compare the extent of chronic unintended left atrial posterior wall isolation after PVI with P-PFA and CB ablation. Methods: We conducted a single-center ambispective study including consecutive patients undergoing repeat left atrial mapping after index PVI with either P-PFA, using a protocol designed to ensure catheter alignment with the pulmonary veins, or CB. Patients with additional LA ablation between index procedure and remapping, unrelated LAPW scarring, or posterior pulmonary vein gaps were excluded. The primary endpoint was isolated LAPW area. Secondary endpoints included percentage of isolated LAPW and minimum residual corridor width. Results: Seventy-four patients were included in the analysis: 49 P-PFA and 25 CB. Mean age was 64.2 ± 10.0 years, 64.9% were male, and 55.4% had persistent AF. Isolated LAPW area was 8.3 ± 4.0 cm 2 in the P-PFA group and 9.5 ± 3.9 cm 2 in the CB group, with no statistically significant difference detected between groups (mean difference −1.26 cm 2 , 95% CI: −3.22 to 0.70; p = 0.203). The percentage of isolated LAPW area was 39.9 ± 17.6% vs. 38.9 ± 14.9% ( p = 0.805), and minimum residual corridor width was 19.7 ± 9.9 vs. 18.6 ± 11.0 mm ( p = 0.671), respectively. P-PFA was associated with shorter procedure time (44.2 ± 10.2 vs. 65.8 ± 24.6 min; p < 0.001), shorter LA dwell time (38.1 ± 9.6 vs. 60.6 ± 20.5 min; p < 0.001), lower fluoroscopy time (5.3 ± 3.9 vs. 13.0 ± 9.7 min; p < 0.001), and lower dose–area product [5.3 (2.8–9.7) vs. 19.3 (6.5–31.0) Gy·cm 2 ; p < 0.001]. Conclusion: In this descriptive, hypothesis-generating study, no statistically significant difference in chronic LAPW isolation extent was detected between P-PFA and CB ablation. These findings support the hypothesis that catheter deployment technique may influence posterior wall lesion geometry, warranting confirmation in adequately powered prospective studies.
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1880750
Open AccessExtent of posterior wall lesion following pulmonary vein isolation with pentaspline pulsed field and cryoballoon ablation: the potential role of deployment technique
Background: Pulmonary vein isolation (PVI) using cryoballoon (CB) or pulsed field ablation (PFA) with a pentaspline catheter achieves similar efficacy in atrial fibrillation (AF), but lesion extension on the left atrial posterior wall (LAPW) may differ. Pentaspline-PFA (P-PFA) has been reported to create broader LAPW lesions, potentially leaving narrow viable corridors that have been hypothesized to be proarrhythmic. Objective: To descriptively compare the extent of chronic unintended left atrial posterior wall isolation after PVI with P-PFA and CB ablation. Methods: We conducted a single-center ambispective study including consecutive patients undergoing repeat left atrial mapping after index PVI with either P-PFA, using a protocol designed to ensure catheter alignment with the pulmonary veins, or CB. Patients with additional LA ablation between index procedure and remapping, unrelated LAPW scarring, or posterior pulmonary vein gaps were excluded. The primary endpoint was isolated LAPW area. Secondary endpoints included percentage of isolated LAPW and minimum residual corridor width. Results: Seventy-four patients were included in the analysis: 49 P-PFA and 25 CB. Mean age was 64.2 ± 10.0 years, 64.9% were male, and 55.4% had persistent AF. Isolated LAPW area was 8.3 ± 4.0 cm 2 in the P-PFA group and 9.5 ± 3.9 cm 2 in the CB group, with no statistically significant difference detected between groups (mean difference −1.26 cm 2 , 95% CI: −3.22 to 0.70; p = 0.203). The percentage of isolated LAPW area was 39.9 ± 17.6% vs. 38.9 ± 14.9% ( p = 0.805), and minimum residual corridor width was 19.7 ± 9.9 vs. 18.6 ± 11.0 mm ( p = 0.671), respectively. P-PFA was associated with shorter procedure time (44.2 ± 10.2 vs. 65.8 ± 24.6 min; p < 0.001), shorter LA dwell time (38.1 ± 9.6 vs. 60.6 ± 20.5 min; p < 0.001), lower fluoroscopy time (5.3 ± 3.9 vs. 13.0 ± 9.7 min; p < 0.001), and lower dose–area product [5.3 (2.8–9.7) vs. 19.3 (6.5–31.0) Gy·cm 2 ; p < 0.001]. Conclusion: In this descriptive, hypothesis-generating study, no statistically significant difference in chronic LAPW isolation extent was detected between P-PFA and CB ablation. These findings support the hypothesis that catheter deployment technique may influence posterior wall lesion geometry, warranting confirmation in adequately powered prospective studies.
- Open Access
- 2 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (9)
Pulmonary vein isolation durability in a randomized trial comparing fluoroscopy-only vs. electroanatomic mapping strategies for pulmonary vein isolation with balloon-in-basket pulsed-field ablation
Aims: Data on long-term durability of pulmonary vein isolation (PVI) with newer pulsed field ablation (PFA) platforms and incremental value of electroanatomic mapping (EAM) guidance remain limited. This study evaluated chronic PVI durability following ablation with a balloon-in-basket PFA catheter and compared outcomes of fluoroscopy-only vs. fluoroscopy plus EAM workflows. Methods and results: In this prospective, single-centre trial, consecutive patients with paroxysmal or persistent atrial fibrillation (AF) underwent de novo PVI with a balloon-in-basket PFA catheter. Patients were randomized 1:1 to fluoroscopy-only or fluoroscopy plus EAM workflow. Systematic invasive remapping was planned >30 days after the index procedure. The dual primary efficacy endpoint was the proportion of pulmonary veins (PVs) and of patients with all PVs durably isolated. The prespecified secondary endpoint was the comparison of procedural characteristics and PVI durability between workflows. Safety outcomes included major adverse events within 30 days of index or remapping procedures. Ninety-six patients (67.4 ± 9.2 years, 44.8% female, 57.3% with paroxysmal AF) underwent index ablation. Fluoroscopy time and number of applications were 3.4 [2.4–4.6] minutes and 15 [13–16], respectively. Systematic remapping was performed in 86 patients at a median of 41 days, with per-vein and per-patient durability of 341/350 (97.4%), and 79/86 (91.9%) respectively. PVI durability and chronic remapping parameters were comparable between guidance strategies. No major adverse events occurred. Conclusion: A standardized balloon-in-basket PFA workflow for PVI achieved high PVI durability. EAM guidance did not confer additional procedural or durability benefit over fluoroscopy-only guidance.
- 2 September 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (9)
Open AccessPulmonary vein isolation durability in a randomized trial comparing fluoroscopy-only vs. electroanatomic mapping strategies for pulmonary vein isolation with balloon-in-basket pulsed-field ablation
Aims: Data on long-term durability of pulmonary vein isolation (PVI) with newer pulsed field ablation (PFA) platforms and incremental value of electroanatomic mapping (EAM) guidance remain limited. This study evaluated chronic PVI durability following ablation with a balloon-in-basket PFA catheter and compared outcomes of fluoroscopy-only vs. fluoroscopy plus EAM workflows. Methods and results: In this prospective, single-centre trial, consecutive patients with paroxysmal or persistent atrial fibrillation (AF) underwent de novo PVI with a balloon-in-basket PFA catheter. Patients were randomized 1:1 to fluoroscopy-only or fluoroscopy plus EAM workflow. Systematic invasive remapping was planned >30 days after the index procedure. The dual primary efficacy endpoint was the proportion of pulmonary veins (PVs) and of patients with all PVs durably isolated. The prespecified secondary endpoint was the comparison of procedural characteristics and PVI durability between workflows. Safety outcomes included major adverse events within 30 days of index or remapping procedures. Ninety-six patients (67.4 ± 9.2 years, 44.8% female, 57.3% with paroxysmal AF) underwent index ablation. Fluoroscopy time and number of applications were 3.4 [2.4–4.6] minutes and 15 [13–16], respectively. Systematic remapping was performed in 86 patients at a median of 41 days, with per-vein and per-patient durability of 341/350 (97.4%), and 79/86 (91.9%) respectively. PVI durability and chronic remapping parameters were comparable between guidance strategies. No major adverse events occurred. Conclusion: A standardized balloon-in-basket PFA workflow for PVI achieved high PVI durability. EAM guidance did not confer additional procedural or durability benefit over fluoroscopy-only guidance.
- 28 May 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 2085-2095
Substrate ablation as concomitant treatment for left atrial macroreentrant tachycardia (SLICE-LAMRT): rationale and study design
Left atrial macroreentrant tachycardias (LAMRTs) are increasing, particularly following atrial fibrillation ablation. Conventional ablation strategies based on activation mapping are limited by the presence of multiple inducible circuits and high recurrence rates. The potential benefit of a substrate-guided approach targeting reproducible anatomical reentry pathways remains unknown. We hypothesize that a substrate-guided approach, targeting reproducible anatomical pathways sustaining reentry rather than only inducible tachycardias, will improve rhythm control and clinical outcomes compared with conventional ablation strategies. The goal of this trial is to determine whether substrate-guided catheter ablation is superior to activation-guided ablation in reducing atrial arrhythmia recurrence in patients with LAMRT. The SLICE-LAMRT trial is an investigator-initiated, prospective, multicenter, randomized (1:1) study conducted at 12 centers in Spain. Patients and clinical event adjudicators are blinded to treatment allocation. Patients with LAMRT and significant left atrial low-voltage substrate are randomized to either a conventional activation-guided ablation strategy, based on high-density mapping and entrainment pacing of clinical and inducible tachycardias, or a substrate-guided approach consisting of a predefined left atrial ablation line set. This study has been registered at ClinicalTrials.gov (NCT05842499). The primary endpoint is atrial tachyarrhythmia recurrence and time to first recurrence after a 3-month blanking period. Secondary endpoints include procedural performance, acute efficacy, major clinical outcomes (including hospitalizations and mortality), and echocardiographic parameters. Safety endpoints include procedure-related adverse events such as death, stroke, cardiac tamponade, vascular complications, and other major complications. The SLICE-LAMRT trial will provide the first randomized evidence comparing substrate-guided and activation-guided ablation strategies in LAMRT. By addressing a major unmet clinical need, this study may inform and refine ablation strategies for atypical atrial flutter and support a shift toward substrate-based approaches in complex atrial arrhythmias.
- 28 May 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 2085-2095
Substrate ablation as concomitant treatment for left atrial macroreentrant tachycardia (SLICE-LAMRT): rationale and study design
Left atrial macroreentrant tachycardias (LAMRTs) are increasing, particularly following atrial fibrillation ablation. Conventional ablation strategies based on activation mapping are limited by the presence of multiple inducible circuits and high recurrence rates. The potential benefit of a substrate-guided approach targeting reproducible anatomical reentry pathways remains unknown. We hypothesize that a substrate-guided approach, targeting reproducible anatomical pathways sustaining reentry rather than only inducible tachycardias, will improve rhythm control and clinical outcomes compared with conventional ablation strategies. The goal of this trial is to determine whether substrate-guided catheter ablation is superior to activation-guided ablation in reducing atrial arrhythmia recurrence in patients with LAMRT. The SLICE-LAMRT trial is an investigator-initiated, prospective, multicenter, randomized (1:1) study conducted at 12 centers in Spain. Patients and clinical event adjudicators are blinded to treatment allocation. Patients with LAMRT and significant left atrial low-voltage substrate are randomized to either a conventional activation-guided ablation strategy, based on high-density mapping and entrainment pacing of clinical and inducible tachycardias, or a substrate-guided approach consisting of a predefined left atrial ablation line set. This study has been registered at ClinicalTrials.gov (NCT05842499). The primary endpoint is atrial tachyarrhythmia recurrence and time to first recurrence after a 3-month blanking period. Secondary endpoints include procedural performance, acute efficacy, major clinical outcomes (including hospitalizations and mortality), and echocardiographic parameters. Safety endpoints include procedure-related adverse events such as death, stroke, cardiac tamponade, vascular complications, and other major complications. The SLICE-LAMRT trial will provide the first randomized evidence comparing substrate-guided and activation-guided ablation strategies in LAMRT. By addressing a major unmet clinical need, this study may inform and refine ablation strategies for atypical atrial flutter and support a shift toward substrate-based approaches in complex atrial arrhythmias.
- Open Access
- 13 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (6)
Optimized workflow for pentaspline PFA and its impact on PVI durability: evidence from systematic remapping
Aims: Real-world series report substantial rates of pulmonary vein (PV) reconnection following index procedure with a pentaspline pulsed-field ablation (P-PFA) catheter. The contrast with initial durability data suggests this may be due to limitations in procedural workflow. Methods and results: We conducted a single-centre, prospective study including consecutive patients undergoing first-time P-PFA pulmonary vein isolation (PVI), subsequently scheduled for systematic invasive remapping ≥30 days after the index procedure. Workflow was progressively refined in three phases, aiming at ensuring adequate tissue contact and based on previous remapping findings. The primary endpoint was PVI durability, per vein and per patient. Of 118 enrolled patients, 94 (Phase 1:n = 30; Phase 2:n = 34; Phase 3:n = 30) underwent systematic remapping, where 13, 10, and 1 reconnected PVs were observed in Phases 1, 2, and 3, respectively. This resulted in per-vein durability of 89.8%, 92.9%, and 99.2% (P = 0.005) and per-patient durability of 60.0%, 76.5%, and 96.7% (P = 0.004). Mean total PFA applications increased from 36.8 ± 5.2 in Phase 1 to 52.1 ± 8.0 and 58.7 ± 15.1 in Phases 2 and 3, respectively (P < 0.001). Median procedure time rose from 43 (39–50) minutes in Phase 1 to 46 (42–56) minutes in Phase 2 and 69 (61–77) minutes in Phase 3 (P < 0.001), with significant parallel increases in LA dwell time (P < 0.001) across phases. No major or minor complications occurred during index or remapping procedures. Conclusion: Progressive workflow refinements for pentaspline P-PFA markedly improved PVI durability to nearly 100%, supporting the concept that PV reconnection is predominantly technique-dependent rather than intrinsic to catheter or waveform design.
- 13 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (6)
Open AccessOptimized workflow for pentaspline PFA and its impact on PVI durability: evidence from systematic remapping
Aims: Real-world series report substantial rates of pulmonary vein (PV) reconnection following index procedure with a pentaspline pulsed-field ablation (P-PFA) catheter. The contrast with initial durability data suggests this may be due to limitations in procedural workflow. Methods and results: We conducted a single-centre, prospective study including consecutive patients undergoing first-time P-PFA pulmonary vein isolation (PVI), subsequently scheduled for systematic invasive remapping ≥30 days after the index procedure. Workflow was progressively refined in three phases, aiming at ensuring adequate tissue contact and based on previous remapping findings. The primary endpoint was PVI durability, per vein and per patient. Of 118 enrolled patients, 94 (Phase 1:n = 30; Phase 2:n = 34; Phase 3:n = 30) underwent systematic remapping, where 13, 10, and 1 reconnected PVs were observed in Phases 1, 2, and 3, respectively. This resulted in per-vein durability of 89.8%, 92.9%, and 99.2% (P = 0.005) and per-patient durability of 60.0%, 76.5%, and 96.7% (P = 0.004). Mean total PFA applications increased from 36.8 ± 5.2 in Phase 1 to 52.1 ± 8.0 and 58.7 ± 15.1 in Phases 2 and 3, respectively (P < 0.001). Median procedure time rose from 43 (39–50) minutes in Phase 1 to 46 (42–56) minutes in Phase 2 and 69 (61–77) minutes in Phase 3 (P < 0.001), with significant parallel increases in LA dwell time (P < 0.001) across phases. No major or minor complications occurred during index or remapping procedures. Conclusion: Progressive workflow refinements for pentaspline P-PFA markedly improved PVI durability to nearly 100%, supporting the concept that PV reconnection is predominantly technique-dependent rather than intrinsic to catheter or waveform design.
- 6 November 2025
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (1) , 153-162
Wide-Antral pulmonary vein isolation in patients undergoing atrial fibrillation ablation with a Single-Shot technique: rationale and design of the WIDER-PVI trial
Background Wide antral circumferential ablation (WACA) is considered the gold standard for pulmonary vein isolation (PVI) in atrial fibrillation (AF) ablation. Single shot devices of increasing diameter, delivering both thermal and pulsed field ablation, are being introduced in clinical practice. However, benefit of ablating larger antral areas on long-term efficacy remains unclear. Objective Our trial aims to determine whether ablation of a larger antral area with a larger single-shot ablation device improves rhythm outcomes compared to traditional single-shot PVI. Methods WIDER-PVI is a prospective, multicenter, randomized controlled trial enrolling patients with paroxysmal AF of any duration or persistent AF diagnosed within the two years prior to ablation. Participants are randomized 1:1 to undergo PVI using either a single-shot device with standard (28-mm cryoballoon, control group) or larger (31-mm cryoballoon, experimental group) antral coverage. The dual primary endpoints are [1] freedom from atrial tachyarrhythmia recurrence lasting >30 s at 12 months, and [2] atrial arrhythmia burden, both assessed via wearable or implantable rhythm monitoring systems. Secondary endpoints include acute procedural metrics (procedure duration, left atrial dwell time, fluoroscopy exposure), need for balloon size crossover, recurrence patterns, repeat ablation rates, and cardiovascular events during follow-up. This study has been registered at ClinicalTrials.gov (NCT06698159). Conclusion WIDER-PVI is the first randomized trial to evaluate whether a larger-diameter single-shot device with enhanced antral coverage improves rhythm outcomes compared to standard single-shot PVI. Its findings may guide future ablation strategies, device design, and clinical decision-making in AF treatment. Graphical Abstract
- 6 November 2025
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (1) , 153-162
Wide-Antral pulmonary vein isolation in patients undergoing atrial fibrillation ablation with a Single-Shot technique: rationale and design of the WIDER-PVI trial
Background Wide antral circumferential ablation (WACA) is considered the gold standard for pulmonary vein isolation (PVI) in atrial fibrillation (AF) ablation. Single shot devices of increasing diameter, delivering both thermal and pulsed field ablation, are being introduced in clinical practice. However, benefit of ablating larger antral areas on long-term efficacy remains unclear. Objective Our trial aims to determine whether ablation of a larger antral area with a larger single-shot ablation device improves rhythm outcomes compared to traditional single-shot PVI. Methods WIDER-PVI is a prospective, multicenter, randomized controlled trial enrolling patients with paroxysmal AF of any duration or persistent AF diagnosed within the two years prior to ablation. Participants are randomized 1:1 to undergo PVI using either a single-shot device with standard (28-mm cryoballoon, control group) or larger (31-mm cryoballoon, experimental group) antral coverage. The dual primary endpoints are [1] freedom from atrial tachyarrhythmia recurrence lasting >30 s at 12 months, and [2] atrial arrhythmia burden, both assessed via wearable or implantable rhythm monitoring systems. Secondary endpoints include acute procedural metrics (procedure duration, left atrial dwell time, fluoroscopy exposure), need for balloon size crossover, recurrence patterns, repeat ablation rates, and cardiovascular events during follow-up. This study has been registered at ClinicalTrials.gov (NCT06698159). Conclusion WIDER-PVI is the first randomized trial to evaluate whether a larger-diameter single-shot device with enhanced antral coverage improves rhythm outcomes compared to standard single-shot PVI. Its findings may guide future ablation strategies, device design, and clinical decision-making in AF treatment. Graphical Abstract
- Open Access
- 31 January 2024
- Published by Wiley
Not another pacemaker-mediated tachycardia
Title: Not another pacemaker-mediated tachycardiaShort title: Not another pacemaker-mediated tachycardiaAuthors: Álvaro Marco del Castillo1, Javier Ramos Jiménez1, Daniel Rodríguez Muñoz1, Adolfo Fontenla Cerezuela1, Luis Borrego Bernabé1, María López Gil1, Rafael Salguero Bodes1, Fernando Arribas Ynsaurriaga1Affiliations: 1Hospital Universitario 12 de Octubre, Madrid, Spain.Fundings: no funding was received in exchange for this scientific material.Conflicts of interest: no conflict of interest exists for any of the authors.
- 31 January 2024
- Published by Wiley
Open AccessNot another pacemaker-mediated tachycardia
Title: Not another pacemaker-mediated tachycardiaShort title: Not another pacemaker-mediated tachycardiaAuthors: Álvaro Marco del Castillo1, Javier Ramos Jiménez1, Daniel Rodríguez Muñoz1, Adolfo Fontenla Cerezuela1, Luis Borrego Bernabé1, María López Gil1, Rafael Salguero Bodes1, Fernando Arribas Ynsaurriaga1Affiliations: 1Hospital Universitario 12 de Octubre, Madrid, Spain.Fundings: no funding was received in exchange for this scientific material.Conflicts of interest: no conflict of interest exists for any of the authors.
- 1 December 2023
- Published by Elsevier in American Heart Journal
- Vol. 269, 15-24
Symptom burden guiding invasive electrophysiological study in paroxysmal supraventricular tachycardia: The believe SVT registry
- 1 December 2023
- Published by Elsevier in American Heart Journal
- Vol. 269, 15-24
Symptom burden guiding invasive electrophysiological study in paroxysmal supraventricular tachycardia: The believe SVT registry
- Open Access
- 20 September 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (6) , 3700-3709
Conduction System Pacing and Atrioventricular Node Ablation in Heart Failure: The PACE-FIB Study Design
Aims: Atrial fibrillation (AF) worsens the prognosis of patients with heart failure (HF). Successful treatments are still very scarce for those with permanent AF and preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction. In this study, the long-term benefits and safety profile of heart rate regularization through left-bundle branch pacing (LBBP) and atrioventricular node ablation (AVNA) will be explored in comparison with pharmacological rate-control strategy. Methods and results: The PACE-FIB trial is a multicentre, prospective, open-label, randomized (1:1) clinical study that will take place between March 2022 and February 2027. A total of 334 patients with HFpEF/HFmrEF and permanent AF will receive either LBBP followed by AVNA (intervention arm) or optimal pharmacological treatment for heart rate control according to European guideline recommendations (control arm). All patients will be followed up for a minimum of 36 months. The primary outcome measure will be the composite of all-cause mortality, HF hospitalization, and worsening HF at 36 months. Other secondary efficacy and safety outcome measures such as echocardiographic parameters, functional status, and treatment-related adverse events, among others, will be analysed too. Conclusion: LBBP is a promising stimulation mode that may foster the clinical benefit of heart rate regularization through AV node ablation compared with pharmacological rate control. This is the first randomized trial specifically addressing the long-term efficacy and safety of this pace-and-ablate strategy in patients with HFpEF/HFmrEF and permanent AF.
- 20 September 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (6) , 3700-3709
Open AccessConduction System Pacing and Atrioventricular Node Ablation in Heart Failure: The PACE-FIB Study Design
Aims: Atrial fibrillation (AF) worsens the prognosis of patients with heart failure (HF). Successful treatments are still very scarce for those with permanent AF and preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction. In this study, the long-term benefits and safety profile of heart rate regularization through left-bundle branch pacing (LBBP) and atrioventricular node ablation (AVNA) will be explored in comparison with pharmacological rate-control strategy. Methods and results: The PACE-FIB trial is a multicentre, prospective, open-label, randomized (1:1) clinical study that will take place between March 2022 and February 2027. A total of 334 patients with HFpEF/HFmrEF and permanent AF will receive either LBBP followed by AVNA (intervention arm) or optimal pharmacological treatment for heart rate control according to European guideline recommendations (control arm). All patients will be followed up for a minimum of 36 months. The primary outcome measure will be the composite of all-cause mortality, HF hospitalization, and worsening HF at 36 months. Other secondary efficacy and safety outcome measures such as echocardiographic parameters, functional status, and treatment-related adverse events, among others, will be analysed too. Conclusion: LBBP is a promising stimulation mode that may foster the clinical benefit of heart rate regularization through AV node ablation compared with pharmacological rate control. This is the first randomized trial specifically addressing the long-term efficacy and safety of this pace-and-ablate strategy in patients with HFpEF/HFmrEF and permanent AF.
- Open Access
- 4 September 2023
- Published by Wiley
Right atrial far-field R-wave jump and delay: new left bundle branch and septal myocardium capture criteria.
Introduction: Left bundle branch area pacing (LBBAP) includes different situations depending on the captured structure. Distinguishing among them may be difficult during daily practice as most criteria are based on intracavitary recordings or precise high-sensibility measurements. The present study aims to determinate new device-based criteria to easily establish left bundle branch and/or deep septal myocardium capture. Methods and Results: the timing of the far-field R-wave electrogram registered at the atrial channel after the onset of the ventricular pacing spike was registered and compared among the modalities of left bundle branch area pacing in consecutive patients receiving dual chamber pacemakers. 46 patients were included. Successful left bundle branch capture was achieved in 67% of the sample, with transition from non-selective to selective left bundle branch pacing (ns-LBBP to s-LBBP) being the most frequent pattern during ventricular threshold test (52%). In those patients, the right atrial appendage far-field R-wave time (RAA-FFT) abruptly prolonged by a mean of 21 ms when transitioning from ns-LBBP to s-LBBP. However, in those whose last captured structure during ventricular threshold test was the deep septal myocardium (uniquely left septal capture or ns-LBBP to left septal transition), no sudden prolongation of the RAA-FFT was observed, remaining unchanged with the shortest values (94 ms vs 115 ms; P 10ms is 100% specific for s-LBBP, whereas a RAA-FFT <105ms indicates deep septal myocardium capture (alone or together with left bundle branch stimulation) with a 91% of probability.
- 4 September 2023
- Published by Wiley
Open AccessRight atrial far-field R-wave jump and delay: new left bundle branch and septal myocardium capture criteria.
Introduction: Left bundle branch area pacing (LBBAP) includes different situations depending on the captured structure. Distinguishing among them may be difficult during daily practice as most criteria are based on intracavitary recordings or precise high-sensibility measurements. The present study aims to determinate new device-based criteria to easily establish left bundle branch and/or deep septal myocardium capture. Methods and Results: the timing of the far-field R-wave electrogram registered at the atrial channel after the onset of the ventricular pacing spike was registered and compared among the modalities of left bundle branch area pacing in consecutive patients receiving dual chamber pacemakers. 46 patients were included. Successful left bundle branch capture was achieved in 67% of the sample, with transition from non-selective to selective left bundle branch pacing (ns-LBBP to s-LBBP) being the most frequent pattern during ventricular threshold test (52%). In those patients, the right atrial appendage far-field R-wave time (RAA-FFT) abruptly prolonged by a mean of 21 ms when transitioning from ns-LBBP to s-LBBP. However, in those whose last captured structure during ventricular threshold test was the deep septal myocardium (uniquely left septal capture or ns-LBBP to left septal transition), no sudden prolongation of the RAA-FFT was observed, remaining unchanged with the shortest values (94 ms vs 115 ms; P 10ms is 100% specific for s-LBBP, whereas a RAA-FFT <105ms indicates deep septal myocardium capture (alone or together with left bundle branch stimulation) with a 91% of probability.
- Open Access
- 27 July 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (9)
Systematic Workflow and Electrogram guidance to reduce X-ray Exposure Time during cryoballoon ablation of atrial fibrillation: the SWEET-Cryo strategy
Cryoballoon pulmonary vein isolation (CB-PVI) offers similar efficacy to point-by-point radiofrequency PVI for patients with atrial fibrillation (AF), but generally with higher X-ray exposure. Strategies aimed at reducing fluoroscopy mostly rely on other costly imaging techniques, limiting their applicability. We designed a Systematic Workflow and Electrogram guidance to reduce X-ray Exposure Time during CB-PVI (SWEET-Cryo) strategy and analysed its impact on fluoroscopy use and acute procedural and clinical outcomes. We enrolled 100 patients with paroxysmal or persistent AF undergoing CB-PVI by two operators with different levels of expertise. Patients treated with the SWEET-Cryo strategy (prospective cohort; n = 50) or conventional fluoroscopy (retrospective control cohort; n = 50) were compared. When applied by the senior operator, the SWEET-Cryo strategy significantly reduced the mean fluoroscopy time (FT) (2.6 ± 1.25 vs. 20.3 ± 10.8 min) and mean dose area product (DAP) (5.1 ± 3.8 vs. 35.3 ± 22.3 Gy cm2) compared with those of the control group, respectively (P < 0.001). Significant reductions in FT (6.4 ± 2.5 min vs. 32.5 ± 10.05) and DAP (13.9 ± 7.7 vs. 92.3 ± 63.8) were also achieved by the less experienced operator (P < 0.001). No difference was observed in acute and long-term complications or freedom from AF between fluoroscopy strategies during a 33-month median follow-up. Mean FT was maintained below 3 min in randomly selected cases performed during the follow-up period. In contrast to conventional protocols and regardless of the operator’s experience, the optimized SWEET-Cryo strategy dramatically reduced fluoroscopy exposure during CB-PVI. The efficacy, safety, or added costs of the ablation procedure were not compromised.
- 27 July 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (9)
Open AccessSystematic Workflow and Electrogram guidance to reduce X-ray Exposure Time during cryoballoon ablation of atrial fibrillation: the SWEET-Cryo strategy
Cryoballoon pulmonary vein isolation (CB-PVI) offers similar efficacy to point-by-point radiofrequency PVI for patients with atrial fibrillation (AF), but generally with higher X-ray exposure. Strategies aimed at reducing fluoroscopy mostly rely on other costly imaging techniques, limiting their applicability. We designed a Systematic Workflow and Electrogram guidance to reduce X-ray Exposure Time during CB-PVI (SWEET-Cryo) strategy and analysed its impact on fluoroscopy use and acute procedural and clinical outcomes. We enrolled 100 patients with paroxysmal or persistent AF undergoing CB-PVI by two operators with different levels of expertise. Patients treated with the SWEET-Cryo strategy (prospective cohort; n = 50) or conventional fluoroscopy (retrospective control cohort; n = 50) were compared. When applied by the senior operator, the SWEET-Cryo strategy significantly reduced the mean fluoroscopy time (FT) (2.6 ± 1.25 vs. 20.3 ± 10.8 min) and mean dose area product (DAP) (5.1 ± 3.8 vs. 35.3 ± 22.3 Gy cm2) compared with those of the control group, respectively (P < 0.001). Significant reductions in FT (6.4 ± 2.5 min vs. 32.5 ± 10.05) and DAP (13.9 ± 7.7 vs. 92.3 ± 63.8) were also achieved by the less experienced operator (P < 0.001). No difference was observed in acute and long-term complications or freedom from AF between fluoroscopy strategies during a 33-month median follow-up. Mean FT was maintained below 3 min in randomly selected cases performed during the follow-up period. In contrast to conventional protocols and regardless of the operator’s experience, the optimized SWEET-Cryo strategy dramatically reduced fluoroscopy exposure during CB-PVI. The efficacy, safety, or added costs of the ablation procedure were not compromised.